CoChat

Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer

Open access
Hwang, Sohyun, Kwon, Ah-Young, Jeong, Ju-Yeon, Kim, Sewha, Kang, Haeyoun, Park, Joonsuk, Kim, Joo-Hang, Han, Ok Jin, Lim, Sun Min, An, Hee Jung · 2020 · Scientific Reports

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Abstract

Immune checkpoint blockade is promising for treating non-small-cell lung cancer (NSCLC). We used multipanel markers to predict the response to immune checkpoint inhibitors (ICIs) by characterizing gene expression signatures or individual genes in patients who showed durable clinical benefit to ICIs. Twenty-one patients with NSCLC treated with single-agent anti-programmed cell death protein (PD)-1 antibody were analyzed and their clinicopathological characteristics and response to ICIs were characterized. Nine (43%) showed a durable clinical benefit (DCB), while the remaining 12 (57%) patients showed non-durable benefit (NDB). The M1 and peripheral T cell signatures showed the best performance for discriminating DCB from NDB (sensitivity, specificity, accuracy = 0.89, 1.0, 0.95, respectively). Progression-free survival (PFS) was significantly longer in patients with high M1 signature or high peripheral T cell signature scores. CD137 and PSMB9 mRNA expression was higher in the DCB group than in the NDB group. Patients with high PSMB9 expression showed longer PFS. M1 signature, peripheral T cell signature and high mRNA expression level of CD137 and PSMB9 showed better predictive performance than known biomarkers, such as PD-L1 immunohistochemistry, tumor mutation burden, or tumor-infiltrating lymphocytes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-019-57218-9

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Heatmap for the 395 immune-related genes from 21 patients. (a) Columns represent patients and rows genes. Expression levels have been aligned according to functional annotation groups. Categories of response (DCB, NDB), PD-L1 expression (≥50%,1–50%, <1%), smoking status (smoker, non-smoker) and histologic subtypes (adenocarcinoma, squamous cell carcinoma, large cell neuroendocrine carcinoma, adenosquamous cell carcinoma) are shown, and tumor infiltrating lymphocytes (TILs) and tumor mutation burden (TMB) are shown in continuous variables. (b) Heatmap for five signature scores of functional annotation groups discriminating DCB and NDB patients. (c) Heatmap for two gene signature scores and two genes that discriminate DCB and NDB patients.
Figure 1 Heatmap for the 395 immune-related genes from 21 patients. (a) Columns represent patients and rows genes. Expression levels have been aligned according to functional annotation groups. Categories of response (DCB, NDB), PD-L1 expression (≥50%,1–50%, <1%), smoking status (smoker, non-smoker) and histologic subtypes (adenocarcinoma, squamous cell carcinoma, large cell neuroendocrine carcinoma, adenosquamous cell carcinoma) are shown, and tumor infiltrating lymphocytes (TILs) and tumor mutation burden (TMB) are shown in continuous variables. (b) Heatmap for five signature scores of functional annotation groups discriminating DCB and NDB patients. (c) Heatmap for two gene signature scores and two genes that discriminate DCB and NDB patients.CC BY · PubMed Central
Figure 2 RNA expressions of gene signatures associated with therapeutic response and improved outcome to anti-PD-1. (a) The expression of M1 signature is significantly higher in DCB group compared to NDB group (t-test, P = 4.95e−4). (b) Patients with high M1 signature have significantly prolonged progression-free survival than those with low M1 signature (log-rank, P = 7.84 e−4). (c) Patients with high M1 signature have similar overall survival than those with low M1 signature (log-rank, P = 0.348). (d) The expression of peripheral T cell signature was significantly higher in DCB group compared to NDB group (t-test, P = 1.08e−4). (e) High peripheral T cell signature was associated with significantly prolonged progression-free survival (log-rank, P = 8.29e−3). (f) Patients with high peripheral T cell signature have similar overall survival than those with low signature (log-rank, P = 0.695).
Figure 2 RNA expressions of gene signatures associated with therapeutic response and improved outcome to anti-PD-1. (a) The expression of M1 signature is significantly higher in DCB group compared to NDB group (t-test, P = 4.95e−4). (b) Patients with high M1 signature have significantly prolonged progression-free survival than those with low M1 signature (log-rank, P = 7.84 e−4). (c) Patients with high M1 signature have similar overall survival than those with low M1 signature (log-rank, P = 0.348). (d) The expression of peripheral T cell signature was significantly higher in DCB group compared to NDB group (t-test, P = 1.08e−4). (e) High peripheral T cell signature was associated with significantly prolonged progression-free survival (log-rank, P = 8.29e−3). (f) Patients with high peripheral T cell signature have similar overall survival than those with low signature (log-rank, P = 0.695).CC BY · PubMed Central
Figure 3 RNA expressions of the genes associated with therapeutic response and improved outcome to anti-PD-1. (a) The RNA expression of the gene CD137 is significantly higher in DCB group compared to NDB group (t-test, P = 2.78e−3) (b). The Kaplan-Meier plots of the patients with high and low RNA expression of each gene indicated that the PFS is higher in the patients with high expressions of CD137, but not statistically significant (log-rank, P = 0.082) (c). The OS does not show statistically significant difference for CD137 (log-rank P = 0.179). (d) The RNA expression of the PSBM9 gene is significantly higher in DCB group compared to NDB group (t-test, P = 6.66e−3).(e). PFS is significantly higher in patients with high PSMB9 RNA expression (log-rank, P = 4.13e−3) (f). OS is similar between two groups (log-rank P = 0.53).
Figure 3 RNA expressions of the genes associated with therapeutic response and improved outcome to anti-PD-1. (a) The RNA expression of the gene CD137 is significantly higher in DCB group compared to NDB group (t-test, P = 2.78e−3) (b). The Kaplan-Meier plots of the patients with high and low RNA expression of each gene indicated that the PFS is higher in the patients with high expressions of CD137, but not statistically significant (log-rank, P = 0.082) (c). The OS does not show statistically significant difference for CD137 (log-rank P = 0.179). (d) The RNA expression of the PSBM9 gene is significantly higher in DCB group compared to NDB group (t-test, P = 6.66e−3).(e). PFS is significantly higher in patients with high PSMB9 RNA expression (log-rank, P = 4.13e−3) (f). OS is similar between two groups (log-rank P = 0.53).CC BY · PubMed Central
Figure 4 Assessment of each marker as predictive biomarker of durable clinical benefit to anti-PD-1 therapy. (a) Predictive abilities of M1 signature, peripheral T cell signature, PD-L1 expression, tumor infiltrating lymphocytes (TIL), and tumor mutation burden (TMB) are compared by receiver operating characteristic (ROC) curves and area under the curve (AUC) values. The points on the curves of PD-L1 expression, TIL, and TMB indicates the cutoff values widely used. (b) Predictive abilities of PSMB9, CD137, PD-L1 expression, TIL, and TMB were compared by ROC curves and AUC values.
Figure 4 Assessment of each marker as predictive biomarker of durable clinical benefit to anti-PD-1 therapy. (a) Predictive abilities of M1 signature, peripheral T cell signature, PD-L1 expression, tumor infiltrating lymphocytes (TIL), and tumor mutation burden (TMB) are compared by receiver operating characteristic (ROC) curves and area under the curve (AUC) values. The points on the curves of PD-L1 expression, TIL, and TMB indicates the cutoff values widely used. (b) Predictive abilities of PSMB9, CD137, PD-L1 expression, TIL, and TMB were compared by ROC curves and AUC values.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Research works printed but not linked: 1

  1. Wickham, H. Elegant Graphics for Data Analysis. (Springer-Verlag 2016).

Cited by

See all 219

Metadata

Authors
Hwang, S., Kwon, A.-Y., Jeong, J.-Y., Kim, S., Kang, H., Park, J., Kim, J.-H., Han, O. J., Lim, S. M., & An, H. J.
Affiliations
CHA University Bundang Medical Center (KR)
Corresponding author
  • Lim, Sun Min
  • An, Hee Jung
Venue
Scientific Reports
Published
2020-01-20
Volume
10
Issue
1
Pages
643-643
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2999372945
Cited by
215
References
51
Citations by year
2026: 10 · 2025: 26 · 2024: 47 · 2023: 39 · 2022: 41 · 2021: 32 · 2020: 19
FWCI
12.28
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Korea Health Industry Development Institute (HI16C1559)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords
non-small cell lung cancer, anti-PD-1 therapy, immune checkpoint inhibitors, immune-related gene signature, durable clinical benefit, predictive biomarkers, 4-1BB, PSMB9, progression-free survival, PD-L1 immunohistochemistry, tumor mutational burden, tumor-infiltrating lymphocytes
MeSH terms
Antineoplastic Agents, Immunological, Nivolumab, Aged, Carcinoma, Non-Small-Cell Lung, Cysteine Endopeptidases, Female, Forecasting, Humans, Immunotherapy, Lung Neoplasms, Male, Middle Aged, T-Lymphocytes, Gene Expression, Treatment Outcome, Tumor Necrosis Factor Receptor Superfamily, Member 9, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer. https://app.cochat.ai/papers/10.1038/s41598-019-57218-9
The paper
Hwang, S., Kwon, A.-Y., Jeong, J.-Y., Kim, S., Kang, H., Park, J., Kim, J.-H., Han, O. J., Lim, S. M., & An, H. J. (2020). Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer. Scientific Reports. https://doi.org/10.1038/s41598-019-57218-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.